Evotec is a leader in the discovery and development of novel small molecule drugs. The Company has established a powerful platform that is applicable to targets across all therapeutic areas and has specific expertise in the area of Central Nervous System (CNS) related diseases where it is building a pipeline of drug candidates for partnering. Through research collaborations and proprietary projects Evotec is providing the highest quality research results to its partners in the pharmaceutical and biotechnology industries.
Evotec's proprietary projects specialise in finding new treatments for diseases of the Central Nervous System (CNS). The focus of research is on major CNS related conditions, including sleep disorders, Alzheimer's disease, pain management and smoking cessation - fast growing therapeutic areas with large unmet medical needs. Evotec has a diverse product pipeline with candidates at various stages of development. The Company's most advanced product candidate, which has recently completed Phase II clinical trials with excellent results, is EVT 201, a partial positive allosteric modulator of the GABAA receptor complex for the treatment of insomnia. Through selective in-licensing and the use of its platform for internal discovery efforts, Evotec intends to further develop and expand its preclinical and clinical CNS pipeline for partnering.